iPREVENT
Trial Details
- Trial statusSetup
- Study email contactiPREVENT@imperial.ac.uk
- Chief InvestigatorProfessor Gary Frost
- Project managerAisha Anjum
- SponsorImperial College Academic Health Science Centre
- ISRCTN numberTbc
- PhaseN/A - non-IMP: dietary supplement
- View clinicaltrials.gov website
- View dedicated study website
Increase in colonic PRopionate as a method of prEVENTing weight gain in young adults
Design and Objective
This is a randomised, placebo-controlled, double-blind trial to investigate the impact of Inulin Propionate Ester (IPE) on weight gain prevention in young adults at high risk of weight gain. 270 participants will be randomised to either IPE or Inulin-control for 12 months. The trial will be conducted at two UK participating sites; Imperial College London and University of Glasgow.
Key inclusion criteria
20-35 years of age BMI 25-30kg/m2 and at least one of the following: - weight gain of 2kg over the last 12 months - low physical activity (‘inactive’ or ‘minimally active’ as per IPAQ) - low fruit and vegetable intake (<2 servings of fruit and vegetables per day) - high intake of sugar sweetened beverages (>1 serving per day) On stable medication